Tarsus Pharmaceuticals, Inc. (TARS) stock
TARSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/309% above fair value
$78.68−1.60 (-1.99%)
Close on Nov 16, 2026Market cap $3.45BP/E –Yield 0.00%
Tarsus Pharmaceuticals profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Tarsus Pharmaceuticals's profit margin for the twelve months ending Jun 30, 2026 was -7.7%. For fiscal 2025 it was -14.7%, against -63.2% the year before. The highest annual figure on record is -14.7% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -14.7% | +48.4 |
| FY2024 | Dec 31, 2024 | -63.2% | +715.7 |
| FY2023 | Dec 31, 2023 | -778.9% | −538.4 |
| FY2022 | Dec 31, 2022 | -240.5% | −216.3 |
| FY2021 | Dec 31, 2021 | -24.2% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -10.7% | +9.1 |
| Q1 FY2026 | Mar 31, 2026 | -4.3% | +27.8 |
| Q4 FY2025 | Dec 31, 2025 | -5.5% | +29.3 |
| Q3 FY2025 | Sep 30, 2025 | -10.6% | +38.1 |
| Q2 FY2025 | Jun 30, 2025 | -19.8% | +61.8 |
| Q1 FY2025 | Mar 31, 2025 | -32.1% | +97.3 |
| Q4 FY2024 | Dec 31, 2024 | -34.8% | +285.6 |
| Q3 FY2024 | Sep 30, 2024 | -48.7% | +2043.7 |
| Q2 FY2024 | Jun 30, 2024 | -81.6% | +855.2 |
| Q1 FY2024 | Mar 31, 2024 | -129.4% | +6.6 |
| Q4 FY2023 | Dec 31, 2023 | -320.4% | −282.9 |
| Q3 FY2023 | Sep 30, 2023 | -2092.4% | +1662.4 |
| Q1 FY2023 | Mar 31, 2023 | -936.8% | +3457.0 |
| Q4 FY2022 | Dec 31, 2022 | -136.0% | +1129.9 |
| Q2 FY2022 | Jun 30, 2022 | -37.6% | −66.4 |
| Q1 FY2022 | Mar 31, 2022 | -3754.7% | −3785.8 |
| Q4 FY2021 | Dec 31, 2021 | -4393.8% | – |
| Q3 FY2021 | Sep 30, 2021 | -1265.9% | – |
| Q2 FY2021 | Jun 30, 2021 | 28.8% | – |
| Q1 FY2021 | Mar 31, 2021 | 31.0% | – |
See a number that looks wrong?